Head honcho

Houston biopharmaceutical company brings on new CEO to grow company

A Houston biotech company has a new CEO and is ready for growth. Getty Images

With a veteran of the biopharmaceutical industry now aboard as its CEO and an executive at pharmaceutical giant AstraZeneca now serving on its board, Houston-based biopharmaceutical company Pulmotect Inc. is poised for progress.

In September, Dr. Colin Broom joined Pulmotect as CEO. He previously was CEO of Ireland-based Nabriva Therapeutics plc, a biopharmaceutical company that went public in 2015. During Broom's tenure at Nabriva, he helped develop the recently approved drug Xenleta, which treats bacterial pneumonia. Before that, he was chief scientific officer at Pennsylvania-based pharmaceutical company ViroPharma Inc., which Massachusetts-based Shire plc purchased for $4.2 billion in 2014.

Broom's hiring came on the heels of Kumar Srinivasan being named to Pulmotect's board of directors. Srinivasan is vice president of United Kingdom-based AstraZeneca and is its global head of business development and licensing for biopharmaceuticals R&D.

Researchers at MD Anderson Cancer Center and Texas A&M University invented Pulmotect's main product, PUL-042, which holds patents in nine countries. Pulmotect, founded in 2007, emerged from Houston's Fannin Innovation Studio, which nurtures early stage companies in the life sciences sector.

"Attracting such a highly regarded and proven CEO as Colin is a clear signal of the power and potential of Pulmotect's development program," Pulmotect's executive chairman, Leo Linbeck III, founder and chairman of Fannin, says in a release. "Under his leadership, I'm confident that we will advance our technology further into the clinic and closer to the marketplace. His addition is a real game-changer for the company."

Both Broom and Srinivasan are focusing on clinical trials for Pulmotect's PUL-042 product, an inhaled therapy that holds the potential to prevent or treat respiratory infections caused by bacteria, viruses, or fungi. The current Phase 2 trial is evaluating the effectiveness of PUL-042 in treating patients with mild chronic obstructive pulmonary disease (COPD) who've been exposed to a respiratory virus. The current trial is supposed to be followed by additional Phase 2 trials.

COPD, which affects 30 million Americans, is the No. 3 cause of death in the U.S., according to the COPD Foundation. Pulmotect says 40 percent of COPD-related costs could be avoided by preventing complications and hospitalizations, which typically result from COPD problems triggered by a bacterial or viral infection. PUL-042 could substantially decrease those complications, the company says.

Pulmotect seeks to gear PUL-042 toward patients with cancer who are undergoing chemotherapy, as their weakened immunity makes them highly susceptible to pneumonia, Broom says. If the product proves effective with those patients, then people at risk of developing respiratory infections also might benefit from it, including COPD patients and flu patients, he says.

To date, Pulmotect has raised more than $28 million in funding. That includes about $18 million in research grants, including a $7 million grant from the Cancer Prevention and Research Institute of Texas, as well as seven grants from the Small Business Innovation Research program.

Two of Pulmotect's three full-time employees work in Houston, and a team of consultants supports their work, Broom says. A small number of employees might be added during the current Phase 2 trial. Hiring would need to be ramped up if the Phase 2 trial demonstrates that PUL-042 works, he says.

Trending News

Building Houston

 
 

This week's Houston innovators to know include Liongard CEO Joe Alapat, Church Space Founder Day Edwards, and PDR Principal Larry Lander. Photos courtesy

As Houston transitions into summer, the city's tech and innovation ecosystem enters a new season — but with the same level of entrepreneurialism and can-do spirit.

This week's innovators to know includes a Houston tech founder fresh off fundraising, an architect with the future of the workplace, and a startup leader with a way to digitally connect churches to their congregations.

Joe Alapat, CEO and co-founder of Liongard

Courtesy of Liongard

After raising a $17 million round for his startup, Joe Alapat, CEO of Liongard, joined the Houston Innovators Podcast to discuss fundraising during a pandemic and how he's seen the Houston innovation ecosystem grow.

In the episode, Alapat also shares his advice for Houston startups looking to tap into the Houston innovation ecosystem — something he's watched grow over the past five years. Now, he says, when it comes to new startups in Houston, "the waves are hitting the shore."

"Houston has always been an entrepreneurial city, and this is just that next stage," Alapat says on the episode. "For me, it's the technology side that excites me even more to see technology companies really succeeding." Listen to the episode and read more.

Day Edwards, founder and CEO of Church Space

Photo courtesy of Church Space

Large gathering places have been shut down for months at this point, and that includes places of worship. Houston entrepreneur Day Edwards, founder and CEO of Church Space, usually focuses on connection organizations to spaces for worship or events. But, she is now focused on getting services online for congregations to connect with.

"It felt like the perfect opportunity to give churches a way to reach more people during the pandemic," says Edwards. "This would create more impact than anything we could possibly offer at this time." Read more.

Larry Lander, principal at PDR

Photo courtesy of PDR

While much of the country has been working from home for weeks, Larry Lander opines that this has made physical office space more important than ever.

"As a place to provide a technology offering we don't enjoy at our kitchen table, as a place to better support small group work beyond the tiny real estate of our laptop screens, and as a place that physically represents what our organizations are truly all about," he writes in a guest column for InnovationMap. The role of the workplace has never been more critical to business success." Read more.

Trending News